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A B S T R A C T
Purpose
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Hereditary factors play a role in the
development of PDAC in 3% to 5% of all patients. Surveillance of high-risk groups, may facilitate
detection of PDAC at an early stage. The aim of this study was to assess whether surveillance aids
detection of early-stage PDAC or precursor lesions (PRLs) and improves the prognosis.
Patients and Methods
Screening outcomeswere collected from three European centers that conduct prospective screening in
high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families
with a gene defect that predisposes to PDAC. The surveillance program consisted of annual magnetic
resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound.
Results
Four hundred eleven asymptomatic individuals participated in the surveillance programs, including 178
CDKN2A mutation carriers, 214 individuals with FPC, and 19 BRCA1/2 or PALB2 mutation carriers. PDAC
was detected in 13 (7.3%) of 178 CDKN2Amutation carriers. The resection rate was 75%, and the 5-year
survival rate was 24%. Two CDKN2Amutation carriers (1%) underwent surgical resection for low-risk PRL.
Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one
early grade 2 neuroendocrine tumor. Thirteen individualswith FPC (6.1%) underwent surgical resection for a
suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous
neoplasms or grade 3 pancreatic intraepithelial neoplasms). One BRCA2mutation carrier was found to have
PDAC, and another BRCA2 mutation carrier and a PALB2 mutation carrier underwent surgery and were
found to have low-risk PRL. No serious complications occurred as consequence of the program.
Conclusion
Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a
resectable stage. The benefit of surveillance in families with FPC is less evident.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) has
a poor prognosis, with a 5-year survival rate of
only 5%.1 Despite progress in our understanding
of PDAC development and improvements in
surgical techniques, the survival rate has not
substantially changed since the introduction of
pancreaticoduodenectomy 80 years ago. Currently,
surgical resection is the only potentially curative
treatment for PDAC, but in approximately 80%
of symptomatic patients, the tumor is already
unresectable at the time of diagnosis. Improve-
ment in the resectability of tumors requires de-
tection of PDAC at an earlier stage. Selective
screening of individuals at high risk for PDAC
might be one way to reach this goal.
Hereditary factors play a role in the devel-
opment of PDAC in 3% to 5% of all patients,2 and
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individuals at increased risk of developing PDAC can be subdivided
into those with an underlying gene defect such as CDKN2A,
BRCA1/2, PALB2, and STK11mutations and those individuals with
a significant family history of PDAC (familial pancreatic cancer
[FPC]).3 The risk of PDAC varies from 5% to 36% depending on
the underlying gene defect.4-7 Disease risk in FPC depends on the
number of relatives with PDAC and varies from 8% (two relatives)
to 30% (three relatives).3
Surveillance of these high-risk groups may lead to early
detection of PDAC or detection of precursor lesions (PRLs),
allowing curative surgical treatment. However, before undertaking
surveillance on a global scale, we need to first establish whether the
surveillance programmeets the screening criteria set out byWilson
and Jungner.8 Surveillance of individuals at high risk for PDAC
complies with most of these requirements. The target group (ie,
individuals with a substantial risk of PDAC [. 10%]) is well
defined. Although the natural history of the disease is not com-
pletely known, studies have reported that patients with FPC as
well as carriers of a CDKN2A mutation frequently develop
PRLs including pancreatic intraepithelial neoplasms (PanINs)
and intraductal papillary mucinous neoplasms (IPMNs).9
Surveillance tools (magnetic resonance imaging [MRI], mag-
netic resonance cholangiopancreatography [MRCP], and endo-
scopic ultrasound [EUS]) that are able to detect small PRLs are
available.10-14 The surveillance program does not seem to be bur-
densome for the patients.15 However, it is not yet knownwhether the
surveillance program meets the most important criteria, which are
the early detection of cancer or PRLs and an improved prognosis.
Previous studies reported data on the yields of surveillance but did
not address the benefit of programs in terms of survival.10-14,16-21
In the current study, we evaluated the long-term outcome of
prospective surveillance of a large series of CDKN2A/p16-Leiden
mutation carriers, BRCA1/2 and PALB2 mutation carriers, and
individuals at risk (IARs) for FPC conducted at three expert centers
in Marburg, Germany; Leiden, the Netherlands; and Madrid,
Spain. The aim of the study was to assess whether surveillance
leads to detection of early-stage PDAC or to the detection of




The current study was made possible through the collaboration of
three tertiary referral centers: the Department of Surgery at Philipps
University in Marburg, the Department of Medical Oncology at Ramon y
Cajal University Hospital in Madrid, and the Department of Gastro-
enterology at Leiden UniversityMedical Center in Leiden. The study design
was a retrospective evaluation of an ongoing prospective follow-up study.
The three centers have conducted screening programs for IARs for PDAC
over the past 4 to 15 years. The number of high-risk individuals and the
type of hereditary PDAC or type of familial PDAC (ie, families with two
first-degree relatives with PDAC [FPC2] or families with at least three first-
degree relatives with PDAC [FPC3]) in the three centers are listed in
Table 1. Only asymptomatic individuals were offered surveillance.
A detailed description of patient selection has been published
previously.22,23 At Leiden University Medical Center, individuals with the
Dutch founder mutation, a 19-base pair deletion of exon 2 of the CDKN2A
gene p16-Leiden, were referred to the Department of Gastroenterology by
a clinical geneticist. Only patients with a proven CDKN2A mutation or
individuals diagnosed with a personal history of melanoma and a known
mutation in the family were selected for the program. At Philipps Uni-
versity, a national registry for families with familial PDAC (the FaPaCa
Registry) was established in 1999.24 Individuals from families with two or
three first-degree relatives with PDAC were offered surveillance. Members
of FPC families were also recruited through physician referral, the
counseling office of the Deutsche Krebshilfe, or the FaPaCa Web site. In
Madrid, patients were selected through a case-control study of patients
with newly diagnosed pancreatic cancer and through 17 familial cancer
units set up in Spain.25
Table 1. Distribution of Individuals at High Risk for PDAC Under Surveillance at the Three Expert Centers
Factor
City and Country of Center
Marburg, Germany Leiden, the Netherlands Madrid, Spain
Year surveillance program began 2002 2000 2010
Current surveillance recommendation From 2002-2011 annual MRI, MRCP, and EUS;
from 2011 to present annual MRI and MRCP,
EUS every 3 years or in case of
suspicious MRI
Annual MRI; since 2012
option for EUS
Annual MRI and EUS
No. of high-risk individuals per group at
January 1, 2015
FPC2 114 — 20
FPC3 70 — 10
CDKN2A/p16-Leiden — 178 —
BRCA2/PALB2 12 2 5
Sex, No. of individuals
Male 81 72 24
Female 115 106 11
Total No. of MRI surveillance examinations
at January 1, 2015
622 866 45
Total No. of surveillance EUSs at January 1, 2015 363 106 72
Average age at start of surveillance, years (range) 45.5 (25-73) 56 (37-75) 46.6 (29-81)
Average follow-up time, years (range) 3.4 (0.0-10.8) 4.4 (0.0-14.1) 1.3 (0.0-3.3)
Abbreviations: EUS, endoscopic ultrasound; FPC2, families with two first-degree relatives with familial pancreatic cancer; FPC3, families with at least three first-degree
relatives with familial pancreatic cancer; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; PDAC, pancreatic ductal
adenocarcinoma.
2 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Vasen et al
145.88.209.33
Information downloaded from jco.ascopubs.org and provided by at WALAEUS LIBRARY on April 29, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
In Leiden, surveillance started at the age of 45 years. In Marburg and
Madrid, surveillance started at age 40 or 10 years earlier than the youngest
age at diagnosis in the family.
The current study is an update of the outcome of surveillance that
was published previously.22,23 All participants were fully informed of the
advantages and disadvantages of the program. The study was approved
by the ethics committees of the respective centers.
Surveillance Protocol
The CDKN2A/p16-Leiden mutation carriers in Leiden were invited
for an annual MRI/MRCP. Beginning in 2012, EUS was also offered as an
option in addition to annual MRI. In the event of a small lesion, MRI was
repeated 3 to 6 months later. In cases where there was serious suspicion of
PDAC, additional EUS and CT scanning was performed. The surveillance
program in Marburg included annual screening by MRI with MRCP and
EUS between 2002 and 2010. Since 2011, follow-up imaging consisted of
annual MRI with MRCP and EUS every third year or in case of suspicious
MRI findings. If there was suspicion for a significant abnormality, IARs
underwent repeated imaging after 4 weeks supplemented with EUS-guided
fine-needle aspiration (FNA) in some individuals. The surveillance pro-
gram in Madrid included annual EUS and MRI. All patients with con-
firmed suspicious lesions at the three centers were discussed within a
multidisciplinary team, and a decision was made regarding the need of
surgery. The criteria that were generally used to propose surgery were as
follows: multiple cystic lesions greater than 10 mm, in particular, cystic
lesions that showed significant growth or a solid component; solitary cystic
lesions greater than 30 mm; solid lesions greater than 5 mm confirmed by
MRI, EUS, and CTscanning, especially, those that increase in size; a dilated
main pancreatic duct (. 10 mm); and positive results of a biopsy.
The surveillance protocols used at the three centers are listed in
Table 1. The data collected include number of IARs with a PRL or PDAC,
age at diagnosis and surgery, site of the PRL and cancer, type of surgery,
complications, histologic type of PRL, stage of PDAC, and survival rate of
patients with PDAC. The observation time was from the start of the
screening programs until January 1, 2015. In the evaluation of the sur-
veillance program, we consider the program a success if a high-risk PRL
(PanIN grade 3 lesions or IPMN with high-grade dysplasia) was detected
and treated or an early PDAC (T1N0M0 with negative resection margins)
was resected.
Statistical Analysis
Age-specific cumulative incidence of PDAC in the CDKN2A/p16-
Leiden mutation carriers and the PDAC survival were calculated using
Kaplan-Meier survival analysis. Analysis of the data was conducted using
the SPSS version 23.0 (SPSS, Chicago, IL).
RESULTS
CDKN2A/p16-Leiden Mutation Carriers
Patient characteristics. One hundred seventy-eight CDKN2A
mutation carriers comprising 177 p16-Leiden mutation carriers
and one carrier of a CDKN2A (c.67G.C, G23R) mutation were
included in the study; 106 of these patients (59.6%) were women,
and 72 (40.4%) weremen. Themean age at the start of the program
was 56 years (range, 37 to 75 years), and the mean follow-up time
was 53 months (range, 0 to 169 months). Seventeen patients
(9.6%) were lost to follow-up. A total of 866 MRIs and 106 EUSs
were performed.
Surveillance outcomes: Pancreatic cancer. PDAC was detected
in 13 (7.3%) of the 178 mutation carriers, including eight women
and five men. The mean age at diagnosis was 58 years (range, 39 to
74 years). The cumulative incidence of PDAC was 14% by the age
of 70 years (Fig 1). Five tumors were diagnosed at first screening,
and eight were detected during follow-up. Four tumors were
located in the head of the pancreas, five in the tail, three in the body,
and one in the transition area from head to body (Table 2). Nine
patients underwent surgery, including three who underwent a
distal pancreatectomy, two a Whipple procedure, one a subtotal
pancreatectomy, one a resection of the body and a distal pan-
createctomy, and two a distal pancreatectomy including splenec-
tomy. In five (56%) of the nine patients, the lymph nodes were free
of tumor, and in seven (78%) of nine patients, the resection margin
was free of tumor. Of the four patients who did not undergo


































No. at risk = 178
Fig 1. Cumulative incidence of pancreatic ductal adenocarcinoma for CDKN2A/p16 mutation carriers.
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patient had extensive local disease. The fourth patient was found to
have a small resectable pancreatic lesion but did not undergo
surgical resection as a result of extensive pulmonary metastasis of a
melanoma. The MRI images suggested that the pancreatic mass
was a PDAC and not a melanoma metastasis. The overall resection
rate was 75%.
One patient developed a second PDAC 54 months after a
Whipple procedure of the primary tumor and underwent a distal
pancreatectomy.26 Eight of the 13 patients died; seven patients died
as a result of PDAC, and one patient died as a result of melanoma
metastases. The overall 5-year survival rate was 24% (Fig 2). In
terms of screening efficiency, 14 patients needed to be screened to
detect one PDAC, and a total of 67 MRIs were needed to detect one
PDAC.
Surveillance outcomes: PRLs. In 26 (14.6%) of 178 CDKN2A/
p16-Leiden mutation carriers, a cystic lesion was found. Two
individuals (1%), both women, underwent surgery (Table 2).
In the first patient, the initial MRI/MRCP (2001) at the age of
63 years showed multiple ductectasia in side branches in the body
of the pancreas with a diameter of 15 mm. In 2008, there was slight
growth of the lesion, and an extended distal pancreatectomy was
subsequently performed. Histologic examination revealed multi-
focal PanIN grade 1 to 2 lesions with branch duct (BD) IPMN and
severe multifocal lobulocentric fibrosis. The patient is currently
doing well 7.2 years later.
The second patient underwent aWhipple procedure at the age
of 67 years as a result of a 15-mm solid lesion in the uncinate
process detected at first MRI. Histologic examination revealed an
IPMN gastric type with low-grade dysplasia. Seventeen months
after surgery, the patient has slightly increased serum values of
alkaline phosphatase and g-glutamyltransferase but is asympto-
matic and in a good health.
IARs for FPC
Patient characteristics. This patient group included 214
individuals, including 99 men and 115 women. One hundred
thirty-four individuals were from FPC2 families, and 80 were
from FPC3 families.
Average age at start of the surveillance program was 48.2 years
(range, 27 to 81 years), and the mean follow-up time was 2.8 years
(range, 0.0 to 10.8 years). A total of 618 MRIs and 402 EUSs were
performed as part of the follow-up program.
Surveillance outcomes: Pancreatic cancer. In the FPC group,
the program detected a lesion suspected for PDAC in three female
patients (1.4%). The first patient was a 53-year-old member of an
FPC3 family. She missed two MRI screening visits and was
diagnosed 26 months after the last normal screening visit with a
30-mm solid tumor in the head of the pancreas. The patient
underwent a total pancreatectomy. Histologic examination showed
a ductal adenocarcinoma pT3N1 (nine positive lymph nodes out
of 22) M0 with tumor-free resection margins. The patient died
38 months after surgery as a result of metastatic disease.
The second patient was a 47-year-old member of an FPC3
family. At the first EUS, a 7-mm cystic lesionwas visible in the body
of the pancreas, which was subsequently confirmed by CT scan-
ning. Two years later, the lesion was 10 mm. An EUS-guided FNA
biopsy revealedmalignant cells. The patient subsequently underwent
a distal pancreatectomy and splenectomy. The surgical specimen
showed a serous cystadenoma with atypical changes but no cancer.
This patient is alive 1 year after surgery.
The third individual was a member of an FPC2 family. EUS
at the age of 48 revealed a 5-mm solid lesion in the tail of the
pancreas. FNA biopsy showed a grade 2 neuroendocrine tumor.
After distal pancreatectomy, the surgical specimen showed a T1
grade 2 neuroendocrine tumor, with tumor-free lymph nodes
and resection margins. The patient is alive 2 years after surgery.
Surveillance outcomes: PRLs. Cystic lesions were detected in
112 (52%) of 214 IARs. A total of 13 patients (6.1%) underwent
surgical resection because of suspicious lesions. The average age at
surgery was 56 years (range, 42 to 69 years). Six IARs belonged to
FPC2 families, and seven IARs belonged to FPC3 families.
Suspicious lesions were diagnosed at the first examination in
five IARs (38.5%) and during follow-up in eight IARs (61.5%). The
























Fig 2. Overall survival of CDKN2A/p16 muta-
tion carriers with pancreatic ductal adenocarci-
noma (PDAC) detected during surveillance.
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lesions were mainly located in the pancreatic body and tail of IARs
(n = 11); two IARs had suspicious lesions in the pancreatic head
(Table 3).
Seven patients underwent a distal pancreatectomy, five patients
a total pancreatectomy, and one patient a Whipple procedure.
One additional patient underwent surgical exploration because of
a suspicious lesion, but no abnormalities were found.
High-risk PRLs, including grade 3 PanIN (n = 3) and IPMN
gastric type with high-grade dysplasia (n = 1), were detected
on histopathologic analysis in four (1.9% of all screened cases)




Sex Disorder MRI Findings
Incident or
Prevalent Management Histology Outcome
Cause of
Death




Prevalent Whipple Main duct IPMN
HGD
Alive 30 months after
surgery
—








Died 22 months after
surgery
Klatskin tumor
3 52/F FPC3 Two ductectesia






Alive 55 months after
surgery
—









Alive 49 months after
surgery
—








Alive 16 months after
surgery
—
6 47/M FPC3 10-mm cystic
lesion, head
Incident Whipple Multifocal PanIN
grade 2, BD-
IPMN LGD
Alive 29 months after
surgery
—









Alive 3 months after
surgery
—




PanIN grade 2, BD-
IPMN LGD
Alive 88 months after
surgery
—








Alive 94 months after
surgery
—







Alive 120 months after
surgery
—







Alive 132 months after
surgery
—







Alive 98 months after
surgery
—







Alive 86 months after
surgery
—








9 of 22 nodes
positive,
pT3N1M0

















Alive 13 months after
surgery
—










Alive 28 months after
surgery
—
Abbreviations: AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasound; F, female; FNA, fine-needle aspiration; FPC, familial pancreatic cancer; FPC2,
families with two first-degree relatives with familial pancreatic cancer; FPC3, families with at least three first-degree relatives with familial pancreatic cancer; HGD, high-
grade dysplasia; IPMN, intraductal papillary mucinous neoplasm; LGD, low-grade dysplasia; M, male; MRI, magnetic resonance imaging; PanIN, pancreatic intraepithelial
neoplasm; PDAC, pancreatic ductal adenocarcinoma.
*Patient 15 underwent surgery in Madrid, Spain; all other patients underwent surgery in Marburg, Germany.
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of 13 IARs. Another four IARs revealed multifocal grade 2
PanIN lesions in combination with BD-IPMNs of the gastric
type and/or atypical flat lesions,27 whereas three IARs showed
serous cystadenomas and two IARs showed focal fibrosis
with grade 1B PanIN lesions. Thus, five IARs (2.3%) were
overtreated.
Four of 13 IARs developed postoperative complications,
including three who developed a pancreatic fistula and one
who had had a postoperative bleeding after Whipple resection
at the pancreaticogastrostomy, which could be managed endo-
scopically. Twelve IARs are alive without evidence of relevant
pancreatic lesions after a median follow-up of 52 months. One
female patient developed an adenocarcinoma of the biliary
tract 22 months after surgery and died as a result of liver
failure.
BRCA1/2 or PALB2 Mutation Carriers
Patient characteristics. Nineteen individuals carried a BRCA1/
2 or PALB2 mutation, including seven men and 12 women. One
individual had a BRCA1 mutation, 12 individuals had a BRCA2
mutation, and six individuals had a PALB2 mutation. Average
age at start of the program was 52.6 years (range, 25 to 70 years),
and the average follow-up time was 32.7 months (range, 1 to
119 months).
Surveillance outcomes. In this cohort, only one individual
(3.8%), a woman with a BRCA2 mutation, developed PDAC
(Table 4). The lesion was detected at age 68 years. The previous
MRI 1 year before revealed a small side BD-IPMN at the transition
from head to body. The patient underwent a distal pancreatectomy
that showed a 19-mm lesion in the tail; resection margins were
free, and all lymph nodes were negative (zero of 16 nodes).
Seventeen months after surgery, the patient died as a result of
liver metastasis.
Two individuals underwent surgery for cystic lesions. The first
patient was a 71-year-old woman with a PALB2 mutation. She
underwent a Whipple procedure after finding a 12-mm lesion
on the first MRI and EUS. Histology showed multifocal grade
2 PanIN lesions and BD-IPMNs with low-grade dysplasia. The
patient is in good condition 21 months after surgery. The second
patient was a 67-year-old woman with a BRCA2 mutation.
Multiple cystic lesions (3 to 8 mm) were detected on the first
MRI. She demanded to undergo a total pancreatectomy. His-
tology showed multifocal grade 2 PanIN and atypical flat lesions.
The patient is in good health 10 months after surgery.
DISCUSSION
The current study demonstrated that the resection rate of screen-
detected PDAC in CDKN2A/p16-Leiden mutation carriers (75%)
was much higher than reported for sporadic PDAC patients (15%
to 20%) and for historical controls of CDKN2A/p16-Leiden
mutation carriers with symptomatic PDAC (15%).23 The 5-year
survival rate was substantially higher (24%) than the survival
rate reported for patients with symptomatic sporadic PDAC (4%
to 7%).28
PRLs were much more frequent in patients with FPC than in
CDKN2A/p16-Leiden mutation carriers. Surgical resection was
performed in 13 patients (6.1%) with FPC. According to the
definition of high-risk lesions proposed by the expert group,29 only
four lesions (1.9% of all screened patients) were high-risk lesions
(grade 3 PanIN or high-grade gastric-type IPMN). However,
another four IARs showed multifocal grade 2 PanIN lesions in
combination with low-grade gastric-type BD-IPMNs and/or
atypical flat lesions. Thus, the question arises of whether multi-
focal grade 2 PanIN lesions and low-grade IPMNs are also relevant
PRLs for PDAC in the setting of FPC. In a large autopsy study,
grade 2 PanIN lesions (previously referred to as atypical hyper-
plasia or low-grade dysplasia) were reported in 29% of patients
with PDAC and only 0.7% of individuals without PDAC, sug-
gesting that grade 2 PanIN lesions are also strongly associated with
PDAC development.30 Although the time interval and rate at
which grade 2 PanIN lesions progress to invasive cancer is
unknown, one can hypothesize that multifocal grade 2 PanIN
lesions and atypical flat lesions are biologically relevant in the
setting of FPC.27
The strengths of the current study were the design as a
prospective long-term follow-up study and the inclusion of a large
series of high-risk individuals. In addition, family history in




Sex Disorder MRI Findings
Incident or
Prevalent Management Histology Outcome Cause of Death
1 68/F BRCA2 Solid lesion (17 3













2 71/F PALB2 Multiple cystic
lesions (3-7 mm)
in head






3 67/F BRCA2 Multiple cystic
lesions (3-8 mm)








Abbreviations: AFL, atypical flat lesion; BD, branch duct; F, female; IPMN, intraductal papillarymucinous neoplasm; LGD, low-grade dysplasia; MRI, magnetic resonance
imaging; PanIN, pancreatic intraepithelial neoplasm; PDAC, pancreatic ductal adenocarcinoma.
*All patients underwent surgery in Marburg, Germany.
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patients with FPC was verified by medical and pathology reports in
greater than 95% of all patients. Furthermore, all participants in
the Leiden series were found to have either a CDKN2A mutation
or a personal history of melanoma and a close relative with a
CDKN2A mutation. A weakness of the study was the lack of a
control group.
One of the most important criteria defined by Wilson and
Jungner8 was that surveillance should improve prognosis. Without
a control group, it is difficult to determine with certainty the effects
of the surveillance program on PDAC outcome. However, in view
of the high resection rate and the better survival compared with the
survival rates reported for patients with sporadic PDAC, sur-
veillance of CDKN2A/p16-Leiden carriers complies with this
requirement.
However, whether surveillance of FPC families meets this
criterion is still questionable. The yield of PDAC is low (0.9%),
and most screen-detected PDACs reported in the literature
were advanced cancers.3 Likewise, the yield in terms of
detection of relevant PRLs (grade 3 PanIN and high-grade
IPMN) was low (1.9%). However, if surgical removal of multi-
focal grade 2 PanIN and multifocal BD-IPMNs is regarded
as beneficial, the diagnostic yield increases to 3.7% (eight of
214 patients), and surveillance of FPC might also be considered
effective.
In summary, surveillance of CDNK2A mutation carriers
was relatively successful, detecting most PDACs at a resect-
able stage. The value of surveillance of FPC is still not clear,
and the main effect seems to be prevention of PDAC by removal
of PRLs.
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No relationship to disclose
Christoph Schicker
No relationship to disclose
Martin Steinkamp
No relationship to disclose
Jens Figiel
No relationship to disclose
Irene Esposito
Research Funding: Novartis (Inst)
Travel, Accommodations, Expenses: Roche Austria
Evelina Mocci
No relationship to disclose
Enrique Vazquez-Sequeiros




No relationship to disclose
José Montans
Honoraria: Cellgene Espana S.L.
Peter Langer
No relationship to disclose
Volker Fendrich
No relationship to disclose
Detlef K. Bartsch
No relationship to disclose
www.jco.org © 2016 by American Society of Clinical Oncology
Long-Term Surveillance of High-Risk Groups for Pancreatic Cancer
145.88.209.33
Information downloaded from jco.ascopubs.org and provided by at WALAEUS LIBRARY on April 29, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank F.J. Hes, R.A. Veenendaal, A. Inderson, N.A. Gruis, J. Dengler, T.M. Gress, P.H. Kann, A. Mahnken, and A. Ramaswamy for
contributing to this article.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Vasen et al
145.88.209.33
Information downloaded from jco.ascopubs.org and provided by at WALAEUS LIBRARY on April 29, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
